objectiveangiotensin
convert
enzym
endogen
counterregul
reninangiotensin
system
relationship
solubl
myocardi
function
clinic
outcom
patient
chronic
systol
heart
failur
well
establish
methodsw
measur
activ
patient
chronic
systol
heart
failur
left
ventricular
eject
fraction
lvef
nyha
class
iiiv
comprehens
echocardiographi
perform
time
blood
sampl
prospect
examin
advers
clinic
event
death
cardiac
transplant
heart
failur
hospit
month
resultspati
higher
plasma
activ
like
lower
lvef
spearman
r
p
greater
rv
systol
dysfunct
p
higher
estim
pulmonari
arteri
systol
pressur
larger
lv
end
diastol
diamet
higher
plasma
ntprobnp
level
p
less
associ
diastol
dysfunct
similar
patient
ischem
nonischem
cardiomyopathi
relationship
activ
marker
system
inflamm
adjust
ntprobnp
lvef
activ
remain
independ
predictor
advers
clinic
event
ci
conclusionselev
plasma
activ
associ
greater
sever
myocardi
dysfunct
independ
predictor
advers
clinic
event
exogen
pharmacolog
inhibit
classic
reninangiotensinaldosteron
system
raa
result
import
clinic
progress
treatment
heart
failur
highlight
detriment
effect
pathway
play
heart
failur
physiolog
failur
adequ
inhibit
raa
associ
increas
morbid
mortal
patient
heart
failur
result
effort
put
forth
understand
regul
raa
therefor
great
interest
new
member
pathway
recent
discov
angiotensin
convert
enzym
ace
homologu
act
novel
endogen
inhibitor
raa
therebi
protect
heart
failur
pathogenesi
deleteri
effect
raa
primarili
relat
increas
product
angiotensin
ii
ang
ii
result
numer
pathophysiolog
sequela
includ
promot
hypertens
cardiac
hypertrophi
adrenerg
activ
review
counteract
effect
ang
ii
two
relat
mechan
integr
membran
carboxypeptidas
remov
termin
aminoacid
ang
ii
net
effect
similar
combin
ace
inhibitor
angiotensin
receptor
blocker
arb
therapi
interestingli
degrad
product
biolog
activ
peptid
ang
bind
ma
receptor
induc
vasodil
action
nitric
oxid
infus
ang
ang
analogu
postinfarct
anim
prevent
develop
heart
failur
indic
activ
cardioprotect
ang
ma
axi
may
possess
therapeut
util
clinic
studi
initi
hamper
requir
obtain
invas
cardiac
tissu
sampl
measur
group
recent
demonstr
membran
cleav
solubl
form
activ
measur
human
plasma
elev
patient
heart
failur
primari
object
studi
extend
previou
work
demonstr
clinic
signific
plasma
activ
fail
human
heart
particular
aim
determin
precis
relationship
plasma
activ
cardiac
structur
systol
diastol
perform
overal
prognosi
patient
chronic
systol
heart
failur
hypothes
elev
activ
would
observ
patient
worsen
cardiac
function
may
predict
longterm
clinic
outcom
neurohormon
substudi
adept
assess
doppler
echocardiographi
prognosi
therapi
studi
previous
describ
approv
cleveland
clinic
institut
review
board
inform
consent
ambulatori
patient
stabl
chronic
systol
heart
failur
left
ventricular
eject
fraction
lvef
new
york
heart
associ
function
class
ii
iv
underw
echocardiograph
evalu
systol
diastol
perform
well
plasma
sampl
collect
clinic
event
allcaus
mortal
cardiac
transplant
heart
failur
hospit
prospect
track
schedul
telephon
followup
valid
chart
review
previous
describ
approxim
patient
complet
month
followup
estim
glomerular
filtrat
rate
egfr
calcul
use
modifi
diet
renal
diseas
equat
base
serum
creatinin
age
gender
ethnic
sampl
collect
use
edtaplasma
tube
process
frozen
analyz
cardiac
inflammatori
biomark
measur
commerci
avail
comprehens
transthorac
echocardiographi
perform
use
commerci
avail
hdi
phillip
medic
system
bothel
wa
acuson
sequoia
siemen
medic
solut
usa
inc
malvern
pa
machin
twodimension
color
doppler
imag
perform
standard
parastern
apic
view
diastol
index
includ
pulsewav
doppler
color
mmode
tissu
doppler
imag
acquir
consecut
beat
use
sweep
speed
cm
cm
use
previous
describ
techniqu
classif
diastol
stage
determin
follow
stage
impair
relax
consist
mitral
ea
deceler
time
ms
pulmonari
vein
sd
atrial
revers
ar
cm
stage
ii
pseudonorm
show
mitral
ea
pulmonari
vein
sd
deceler
time
ms
ar
cm
stage
iii
restrict
give
mitral
ea
pulmonari
vein
sd
deceler
time
ms
ar
cm
estim
left
atrial
pressur
determin
pulmonari
vein
sd
e
septal
ea
mitral
evp
ratio
lvef
cardiac
volum
measur
use
simpson
biplan
method
measur
averag
cycl
cycl
atrial
fibril
experienc
individu
blind
neurohormon
data
made
measur
specif
fluorometr
assay
measur
perform
base
quench
fluoresc
substrat
qf
acetylalaproli
r
system
minneapoli
mn
protocol
previous
develop
specif
determin
preincub
plasma
min
specif
human
inhibitor
phoenix
pharmaceut
burlingam
ca
patient
plasma
activ
determin
hour
express
rel
fluoresc
unit
hr
rfuhr
sampl
minu
rfuhr
sampl
presenc
hour
valu
normal
recombin
standard
curv
ngml
r
system
minneapoli
mn
intraassay
variabl
interassay
variabl
plasma
activ
nonnorm
distribut
express
median
interquartil
rang
iqr
valu
deriv
receiv
oper
characterist
analysi
roc
analysi
varianc
kruskalw
test
nonnorm
distribut
data
use
assess
differ
continu
clinic
variabl
across
tertil
accord
whether
distribut
normal
wherea
conting
tabl
analysi
perform
assess
differ
clinic
proport
across
tertil
normal
assess
shapirowilk
w
test
systol
blood
pressur
egfr
ntprobnp
lv
enddiastol
volum
index
lvef
nonnorm
distribut
age
heart
rate
normal
distribut
spearman
rank
correl
method
use
nonparametr
measur
associ
correl
plasma
activ
clinic
variabl
odd
ratio
alter
systol
diastol
perform
calcul
multivari
logist
regress
across
tertil
activ
respect
tertil
odd
ratio
kaplanmei
surviv
plot
calcul
baselin
time
allcaus
mortal
cardiac
transplant
heart
failur
hospit
mean
followup
month
univari
multivari
cox
proport
hazard
analys
also
calcul
allcaus
mortal
cardiac
transplant
heart
failur
hospit
outcom
plasma
activ
treat
either
categor
variabl
tabl
continu
variabl
tabl
tabl
use
categor
variabl
model
differ
outcom
patient
valu
rocderiv
valu
rel
roc
valu
roc
curv
analysi
perform
determin
increment
prognost
valu
activ
ntprobnp
lvef
esept
ea
ratio
p
valu
consid
statist
signific
statist
analys
perform
use
sa
version
jmp
version
sa
institut
inc
cari
nc
studi
cohort
mean
median
plasma
activ
ngml
ngml
iqr
ngml
respect
tabl
demonstr
baselin
clinic
biochem
characterist
cohort
stratifi
tertil
activ
compar
rd
st
tertil
increas
correl
significantli
lv
systol
dysfunct
lv
dilat
also
right
ventricular
rv
systol
dysfunct
increas
estim
pulmonari
arteri
systol
pressur
tabl
plasma
activ
correl
indic
diastol
dysfunct
elev
estim
lv
fill
pressur
although
correl
less
robust
tabl
util
variabl
associ
activ
rv
systol
dysfunct
p
lv
systol
dysfunct
remain
independ
associ
plasma
level
multivari
regress
analysi
probabl
enter
leav
p
relationship
activ
plasma
hscrp
mpo
level
tabl
mean
followup
time
month
patient
experienc
death
cardiac
transplant
experienc
combin
endpoint
death
transplant
heart
failur
hospit
figur
demonstr
longterm
advers
clinic
event
rate
patient
chronic
systol
heart
failur
stratifi
tertil
plasma
activ
patient
highest
tertil
fare
significantli
wors
within
lowest
two
tertil
use
roc
curv
analysi
valu
ngml
gave
area
curv
chisquar
p
patient
ngml
hazard
ratio
hr
p
compar
combin
endpoint
therefor
rocderiv
valu
use
subsequ
analysi
figur
compar
advers
event
rate
patient
stratifi
plasma
activ
ngml
stratifi
median
ntprobnp
level
pg
ml
patient
increas
ntprobnp
level
significantli
wors
clinic
outcom
low
ntprobnp
level
compar
patient
low
likelihood
advers
event
ntprobnp
median
increas
activ
ngml
significantli
increas
event
rate
hr
p
addit
ntprobnp
lvef
esept
ea
significantli
augment
prognost
accuraci
tradit
prognost
factor
either
continu
rocderiv
variabl
tabl
plasma
activ
continu
predict
longterm
clinic
event
even
adjust
tradit
risk
factor
tabl
prognost
abil
limit
combin
endpoint
allcaus
mortal
alon
increas
patient
elev
activ
hr
predict
advers
event
even
patient
sever
systol
dysfunct
restrict
diastol
fill
pattern
figur
raa
play
crucial
role
regul
normal
cardiac
function
perpetu
ultim
detriment
pathway
mediat
progress
heart
failur
target
inhibit
nearli
everi
level
result
import
clinic
progress
treatment
heart
failur
particular
blockad
ang
ii
activ
common
essenti
biolog
system
like
evolv
natur
counterregulatori
mechan
limit
ang
ii
overactiv
mechanist
demonstr
potenti
role
patient
chronic
systol
heart
failur
three
major
find
increas
activ
associ
worsen
lv
rv
systol
function
activ
direct
relationship
marker
system
inflamm
increas
activ
independ
predictor
combin
endpoint
death
cardiac
transplant
heart
failur
hospit
taken
togeth
data
directli
link
sever
heart
failur
impair
cardiac
perform
level
enzymat
activ
reinforc
potenti
import
counterregulatori
pathway
develop
progress
heart
failur
previous
demonstr
plasma
activ
elev
specif
patient
diagnosi
heart
failur
current
studi
expand
investig
found
correl
increas
activ
lv
eject
fraction
one
robust
similarli
anim
studi
demonstr
increas
level
found
within
fail
lv
delet
result
dilat
cardiomyopathi
also
found
correl
strongli
rv
systol
dysfunct
increas
activ
found
rv
lv
patient
primari
pulmonari
hypertens
suggest
compartment
product
respons
stress
pulmonari
hypertensionrel
rv
systol
dysfunct
depend
pressur
overload
shown
import
cardioprotect
factor
respons
cardiac
dysfunct
precipit
pressureoverload
illustr
associ
activ
estim
pulmonari
arteri
systol
pressur
studi
echocardiograph
analysi
patient
singl
nucleotid
polymorph
demonstr
increas
septalwal
thick
cardiac
hypertrophi
variant
although
chang
diastol
indic
note
presum
polymorph
either
alter
express
enzymat
activ
diastol
dysfunct
begin
develop
cardiac
hypertrophi
increas
deposit
collagen
infus
ang
ii
produc
similar
biochem
chang
deliveri
either
ang
prevent
hypertrophi
collagen
deposit
delet
ma
receptor
result
develop
cardiac
hypertrophi
suggest
direct
involv
diastol
function
systol
heart
failur
ma
axi
may
primari
regulatori
step
limit
ang
iiinduc
diastol
dysfunct
therefor
interest
note
contrast
mani
cardiac
inflammatori
biomark
elev
plasma
activ
correl
modestli
worsen
diastol
function
studi
cohort
known
cardioprotect
properti
upregul
patient
heart
failur
although
signific
shed
yet
understood
plasma
releas
may
directli
parallel
membran
express
rel
constant
rate
convers
membran
solubl
form
elev
activ
see
patient
poor
outcom
would
relat
ongo
counterregulatori
respons
albeit
insuffici
elev
ang
ii
level
heart
failur
progress
would
analog
increas
bnp
level
seen
patient
worsen
hf
ubiquit
present
virtual
everi
sampl
test
whether
patient
healthi
control
indic
presenc
plasma
part
normal
physiolog
altern
presenc
increas
plasma
activ
may
relat
upregul
proteas
cleav
membran
therefor
decreas
membran
level
within
myocardium
result
would
worsen
myocardi
ang
iiang
balanc
associ
cardiac
dysfunct
like
multipl
enzym
cleav
membran
indic
multipl
level
regul
enzym
respons
basal
cleavag
yet
identifi
partial
respons
induc
cleavag
upregul
proinflammatori
cytokin
activ
proteas
heart
failur
develop
long
implic
patholog
mechan
cardiac
remodel
increas
oxid
stress
neutrophil
infiltr
seen
mice
identifi
possibl
link
inflamm
cleavag
howev
find
associ
plasma
activ
marker
system
inflamm
hscrp
mpo
suggest
inflamm
involv
cleavag
mechan
differ
promot
creactiv
protein
mpo
secret
outcom
data
put
context
rel
small
event
rate
promis
associ
elev
plasma
activ
especi
third
tertil
develop
advers
clinic
event
particularli
appar
within
group
patient
belowmedian
ntprobnp
level
pgml
presenc
elev
activ
signifi
subset
patient
increas
risk
larger
studi
need
valid
hypothesisgener
result
valid
util
measur
prognost
marker
despit
extens
echocardiograph
evalu
associ
activ
echocardiograph
indic
impli
potenti
relationship
illustr
causeandeffect
similarli
system
inflammatori
biomark
lack
relationship
activ
impli
lack
region
local
inflammatori
oxid
stress
mechan
result
cleavag
cell
membran
fact
identifi
sourc
mechan
respons
cleavag
cell
membran
studi
mention
outcom
data
limit
small
event
rate
nevertheless
approach
pharmacolog
modul
current
develop
data
provid
promis
support
target
manag
human
heart
failur
howev
mechanist
studi
determin
pathophysiolog
implic
shed
whether
focu
futur
therapi
strategi
promot
increas
product
prevent
cleavag
report
key
cardioprotect
counterregulatori
member
raa
elev
patient
worsen
left
right
ventricular
perform
independ
system
inflamm
prognost
indic
advers
clinic
event
angiotensin
convert
enzym
patient
stratifi
base
tertil
plasma
activ
tertil
ngml
tertil
ngml
tertil
ngml
b
ntprobnp
median
ntprobnp
pgml
rocderiv
valu
ngml
angiotensin
convert
enzym
ntprobnp
ntermin
pro
btype
natriuret
peptid
advers
event
rate
calcul
combin
endpoint
death
heart
transplant
heart
failur
hospit
hazard
ratio
calcul
rel
group
level
ngml
median
valu
use
left
ventricular
eject
fraction
lvef
esept
ea
ratio
angiotensin
convert
enzym
p
n
tabl
clinic
characterist
base
tertil
activ
correl
plasma
activ
biochem
echocardiograph
characterist
studi
popul
